Compare Pfizer with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs SHASUN PHARMA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER SHASUN PHARMA PFIZER/
SHASUN PHARMA
 
P/E (TTM) x 33.1 123.9 26.7% View Chart
P/BV x 5.6 8.5 65.1% View Chart
Dividend Yield % 0.6 0.2 263.3%  

Financials

 PFIZER   SHASUN PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-18
SHASUN PHARMA
Mar-14
PFIZER/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,36594 2,510.6%   
Low Rs1,62546 3,563.6%   
Sales per share (Unadj.) Rs430.3214.2 200.9%  
Earnings per share (Unadj.) Rs78.75.3 1,475.0%  
Cash flow per share (Unadj.) Rs93.215.8 589.0%  
Dividends per share (Unadj.) Rs20.001.00 2,000.0%  
Dividend yield (eoy) %1.01.4 70.1%  
Book value per share (Unadj.) Rs586.553.3 1,099.5%  
Shares outstanding (eoy) m45.7556.62 80.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.60.3 1,420.7%   
Avg P/E ratio x25.313.1 193.5%  
P/CF ratio (eoy) x21.44.4 484.5%  
Price / Book Value ratio x3.41.3 259.6%  
Dividend payout %25.418.7 135.6%   
Avg Mkt Cap Rs m91,2713,958 2,306.1%   
No. of employees `0002.6NA-   
Total wages/salary Rs m3,1432,164 145.3%   
Avg. sales/employee Rs Th7,484.8NM-  
Avg. wages/employee Rs Th1,195.0NM-  
Avg. net profit/employee Rs Th1,369.1NM-  
INCOME DATA
Net Sales Rs m19,68512,127 162.3%  
Other income Rs m1,143229 498.3%   
Total revenues Rs m20,82812,356 168.6%   
Gross profit Rs m5,0031,009 495.8%  
Depreciation Rs m663594 111.6%   
Interest Rs m4415 1.0%   
Profit before tax Rs m5,479230 2,385.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,878-73 -2,583.1%   
Profit after tax Rs m3,601302 1,191.8%  
Gross profit margin %25.48.3 305.4%  
Effective tax rate %34.3-31.7 -108.3%   
Net profit margin %18.32.5 734.2%  
BALANCE SHEET DATA
Current assets Rs m24,1676,884 351.0%   
Current liabilities Rs m9,5448,456 112.9%   
Net working cap to sales %74.3-13.0 -573.2%  
Current ratio x2.50.8 311.0%  
Inventory Days Days5562 89.4%  
Debtors Days Days29108 26.7%  
Net fixed assets Rs m9,5144,970 191.4%   
Share capital Rs m458113 403.8%   
"Free" reserves Rs m26,3752,875 917.4%   
Net worth Rs m26,8323,020 888.4%   
Long term debt Rs m251,817 1.4%   
Total assets Rs m36,90013,347 276.5%  
Interest coverage x1,305.51.6 84,046.7%   
Debt to equity ratio x00.6 0.2%  
Sales to assets ratio x0.50.9 58.7%   
Return on assets %9.85.4 181.8%  
Return on equity %13.410.0 134.1%  
Return on capital %20.413.3 153.2%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m225,843 0.4%   
Fx outflow Rs m1,4892,173 68.5%   
Net fx Rs m-1,4663,669 -40.0%   
CASH FLOW
From Operations Rs m3,318398 834.5%  
From Investments Rs m-2,383-1,635 145.7%  
From Financial Activity Rs m-1,1041,309 -84.3%  
Net Cashflow Rs m-16971 -236.7%  

Share Holding

Indian Promoters % 0.0 39.2 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 3.6 208.3%  
FIIs % 4.9 17.6 27.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 39.6 59.8%  
Shareholders   85,207 20,750 410.6%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

DR. LAL PATHLABS LTD at All Time High; BSE HEALTHCARE Index Up 1.7% (Market Updates)

Oct 22, 2019 | Updated on Oct 22, 2019

DR. LAL PATHLABS LTD share price has hit an all time high at Rs 1,550 (up 4.5%). The BSE HEALTHCARE Index is up by 1.7%. Among the top gainers in the BSE HEALTHCARE Index today are DR. LAL PATHLABS LTD (up 4.5%) and PFIZER (up 1.5%). The top losers include SANOFI INDIA and ABBOTT INDIA .

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Oct 22, 2019 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS